Abstract: In an example, an antenna includes a first radiator, a second radiator, a first feed, a first feeder, and a second feeder. The first feed is configured to connect to a radio frequency front-end, is electrically connected to the first radiator through the first feeder, and is electrically connected to the second radiator through the second feeder. When the antenna is in a first operating mode, the first feed feeds a first radio frequency signal into the first radiator and the second radiator, the first radiator and the second radiator receive second radio frequency signals of a same frequency, and the first radiator and the second radiator are coupled to each other and are configured to generate a first resonance.

Abstract: Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.

Abstract: This application provides a housing, a terminal device, and a housing manufacturing method. The housing includes a magnesium-based metal matrix. A first aluminum-based metal layer and a second aluminum-based metal layer are respectively disposed on two sides of the magnesium-based metal matrix, a first transition layer is disposed between the magnesium-based metal matrix and the first aluminum-based metal layer, an appearance layer is disposed on a surface of a side that is of the first aluminum-based metal layer and that is away from the first transition layer, a second transition layer is disposed between the magnesium-based metal matrix and the second aluminum-based metal layer, and an electrical connection layer is disposed on a surface of a side that is of the second aluminum-based metal layer and that is away from the second transition layer.

Abstract: The present invention relates to methods and uses for screening anti-hepadnaviral substances, wherein the substances are screened for the capacity to inhibit covalently closed circular (ccc) DNA of a hepadnavirus, like hepatitis B virus. The methods and uses take advantage of cells comprising a nucleic sequence encoding a tagged hepadnavirus e antigen, like Hepatitis B virus e antigen (HBeAg). Furthermore, the present invention provides nucleic acid sequences encoding a tagged hepadnavirus e antigen and proteins encoded thereby. Also kits for use in the screening methods are provided.

Abstract: The present invention relates to methods and uses for screening anti-hepadnaviral substances, wherein the substances are screened for the capacity to inhibit covalently closed circular (ccc) DNA of a hepadnavirus, like hepatitis B virus. The methods and uses take advantage of cells comprising a nucleic sequence encoding a tagged hepadnavirus e antigen, like Hepatitis B virus e antigen (HBeAg). Furthermore, the present invention provides nucleic acid sequences encoding a tagged hepadnavirus e antigen and proteins encoded thereby. Also kits for use in the screening methods are provided.

Abstract: The present invention relates to methods and uses for screening anti-hepadnaviral substances, wherein the substances are screened for the capacity to inhibit covalently closed circular (ccc) DNA of a hepadnavirus, like hepatitis B virus. The methods and uses take advantage of cells comprising a nucleic sequence encoding a tagged hepadnavirus e antigen, like Hepatitis B virus e antigen (HBeAg). Furthermore, the present invention provides nucleic acid sequences encoding a tagged hepadnavirus e antigen and proteins encoded thereby. Also kits for use in the screening methods are provided.

Abstract: Aspect are disclosed for determining network health based on data from a user device. A processing device can receive information about a network from a user device connected to the network. The processing device can also generate analytics about a health of the network based on the information. The processing device can also provide instructions identifying actions that can be performed to improve the health based on the analytics.

Abstract: A system can include a battery, a processing device, and a memory device. The battery can power a device. The memory device can store instructions are stored for causing the processing device to track data about the battery. The processing device can determine a battery life of the battery based on the data. The battery life can indicate a degradation in the battery over multiple discharge cycles. The processing device can notify a user of the device if the battery life is below a threshold value.

Abstract: A method can include determining that a mobile device is within a communication range of an access point for a first wireless local area network, causing the mobile device to present an interface that receives user input for at least one of authenticating the mobile device or authorizing the mobile device, and connecting the mobile device to the first wireless local area network based on the user input received via the interface. The method can further include determining that the mobile device is within a communication range of an access point for a second wireless local area network, determining a service set identifier for each access point is governed by a common access policy, and connecting the mobile device to the second wireless local area network based on the service set identifiers being governed by the common access policy.

Abstract: The present invention relates to methods and uses for screening anti-hepadnaviral substances, wherein the substances are screened for the capacity to inhibit covalently closed circular (ccc) DNA of a hepadnavirus, like hepatitis B virus. The methods and uses take advantage of cells comprising a nucleic sequence encoding a tagged hepadnavirus e antigen, like Hepatitis B virus e antigen (HBeAg). Furthermore, the present invention provides nucleic acid sequences encoding a tagged hepadnavirus e antigen and proteins encoded thereby. Also kits for use in the screening methods are provided.

Abstract: Pharmaceutical compositions of the invention comprise covalently closed circular DNA formation inhibitors having a disease-modifying action in the treatment of diseases associated with the formation of covalently closed circular DNA that include hepatitis B infection, and any disease involving formation of covalently closed circular DNA.

Abstract: Pharmaceutical compositions of the invention comprise covalently closed circular DNA formation inhibitors having a disease-modifying action in the treatment of diseases associated with the formation of covalently closed circular DNA that include hepatitis B infection, and any disease involving formation of covalently closed circular DNA.